US biotech uses AI to pick antiviral for COVID-19 trial

US biotech AI Therapeutics has begun a phase 2 trial of its LAM-002A, an antiviral drug that has shown promise against the SARS-CoV-2 coronavirus in the lab.

The company develops drugs that have been identified with a proprietary artificial intelligence (AI) algorithm that matches drugs to new indications.